These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Reubi JC; Laissue J; Waser B; Horisberger U; Schaer JC Ann N Y Acad Sci; 1994 Sep; 733():122-37. PubMed ID: 7978860 [TBL] [Abstract][Full Text] [Related]
50. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Ferone D; van Hagen PM; van Koetsveld PM; Zuijderwijk J; Mooy DM; Lichtenauer-Kaligis EG; Colao A; Bogers AJ; Lombardi G; Lamberts SW; Hofland LJ Endocrinology; 1999 Jan; 140(1):373-80. PubMed ID: 9886848 [TBL] [Abstract][Full Text] [Related]
51. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Papotti M; Kumar U; Volante M; Pecchioni C; Patel YC Clin Endocrinol (Oxf); 2001 May; 54(5):641-9. PubMed ID: 11380495 [TBL] [Abstract][Full Text] [Related]
52. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Reubi JC Ann N Y Acad Sci; 2000; 921():1-25. PubMed ID: 11193811 [TBL] [Abstract][Full Text] [Related]
53. 17-beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo. Visser-Wisselaar HA; Van Uffelen CJ; Van Koetsveld PM; Lichtenauer-Kaligis EG; Waaijers AM; Uitterlinden P; Mooy DM; Lamberts SW; Hofland LJ Endocrinology; 1997 Mar; 138(3):1180-9. PubMed ID: 9048625 [TBL] [Abstract][Full Text] [Related]
54. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463 [TBL] [Abstract][Full Text] [Related]
55. [111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors. Maina T; Cescato R; Waser B; Tatsi A; Kaloudi A; Krenning EP; de Jong M; Nock BA; Reubi JC J Med Chem; 2014 Aug; 57(15):6564-71. PubMed ID: 25007399 [TBL] [Abstract][Full Text] [Related]
56. Somatostatin receptors in the developing rat brain. Thoss VS; Duc D; Hoyer D Eur J Pharmacol; 1996 Feb; 297(1-2):145-55. PubMed ID: 8851178 [TBL] [Abstract][Full Text] [Related]
57. Somatostatin receptor subtypes sst1 and sst2 elicit opposite effects on the response to glutamate of mouse hypothalamic neurones: an electrophysiological and single cell RT-PCR study. Lanneau C; Viollet C; Faivre-Bauman A; Loudes C; Kordon C; Epelbaum J; Gardette R Eur J Neurosci; 1998 Jan; 10(1):204-12. PubMed ID: 9753128 [TBL] [Abstract][Full Text] [Related]
59. A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas. Körner M; Waser B; Christ E; Beck J; Reubi JC Neuroendocrinology; 2018; 106(2):116-127. PubMed ID: 28384628 [TBL] [Abstract][Full Text] [Related]
60. Development of selective antibodies against the human somatostatin receptor subtypes sst1-sst5. Helboe L; Møller M; Nørregaard L; Schiødt M; Stidsen CE Brain Res Mol Brain Res; 1997 Oct; 49(1-2):82-8. PubMed ID: 9387866 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]